Aspect Ventures

Aspect Ventures is a useful entry in any directory of healthcare investors precisely because it is no longer making new investments, and that history tells founders something important. Founded in 2014 by Theresia Gouw and Jennifer Fonstad, two of the most senior women in venture, Aspect was built as a deliberate bridge between angel rounds and the larger multi-stage firms that dominate Series B and beyond. The thesis was crisp: lead Series A rounds in cybersecurity, future of work, and digital health, with a stated commitment to backing diverse founding teams. The disclosed portfolio is genuinely impressive. athenahealth, the cloud-based EHR and revenue cycle company, predates the firm but reflects Gouw’s earlier work. Vida Health remains one of the more enduring chronic condition management platforms. Solv built same-day care booking. Eden Health pioneered employer-sponsored hybrid primary care. Future Family financed fertility treatment. Outside healthcare, Cato Networks, Forescout, Chime, Trulia, and Coinbase round out a track record that few seed-stage firms can match.

The stated thesis was to bridge angels and multi-stage VCs, leading or co-leading Series A rounds in cybersecurity, future of work, and digital health, with a sustained focus on diverse founders. The implied target was a team of two to six with early product-market signal, ready for institutional capital but not yet at the scale that draws Sequoia, Andreessen Horowitz, or Benchmark. In digital health specifically, Aspect’s bets concentrated on tech-enabled care delivery, employer health, women’s and reproductive health, and consumer-facing digital health products. The firm explicitly differentiated by underwriting category creators in spaces where incumbents had structural disadvantages. The implication for founders today is largely retrospective: Aspect’s pattern of investment remains a useful reference for what a top-quartile early-stage digital health portfolio looked like in the late 2010s.

The disclosed portfolio shows clear concentration in B2B2C digital health and employer-facing care models. Vida Health, Eden Health, and Solv all share an architecture: software plus services delivered through employer or payer channels, with consumer-facing apps as the engagement layer. Future Family added a consumer financing wrapper to fertility care. athenahealth represents an earlier era of cloud-based provider software. The non-healthcare entries, particularly Cato Networks and Chime, illustrate Aspect’s willingness to underwrite category-creating bets in regulated industries with long sales cycles, a pattern visible across the healthcare positions as well. The takeaway for founders studying Aspect’s history: the firm was right early on telehealth-adjacent care models and on consumer financial services in healthcare-relevant segments.

Check size and stage data list seed and Series A as the active range, with average Series A round sizes around $9M and Aspect frequently leading or co-leading. The firm typically wrote between $1M and $5M as initial checks and reserved heavily for follow-on. Co-investors across the disclosed portfolio include a recurring cast of seed funds, large multi-stage firms at later rounds, and strategic corporate investors in healthcare. Because Aspect is no longer making new investments, founders cannot pitch the firm. The relevant context now is that follow-on for existing portfolio companies effectively wound down after the 2019 split, and surviving portfolio companies have generally moved their primary investor relationships to other firms.

Decision-making during the active years rested with co-founders Theresia Gouw and Jennifer Fonstad. Both partners had pre-Aspect track records that mattered for the firm’s authority. Gouw co-founded Accel Partners’ early-stage practice and led investments in Trulia, Imperva, and others. Fonstad spent two decades at Draper Fisher Jurvetson. Following the 2019 split, Gouw founded Acrew Capital, which carries forward many of the themes Aspect originated, including digital health and female-founder representation. Fonstad has continued investing through other vehicles. Founders interested in pitching the people behind Aspect should research current vehicles rather than the legacy firm.

The practical guidance for founders who land on this profile while researching investor history is straightforward. Aspect’s website and portfolio remain useful as a benchmark for what a healthcare-inclusive Series A portfolio looked like at peak. Gouw’s commentary in publications like The Information and on podcasts including Recode Decode and the Twenty Minute VC remains a strong reference for thinking about Series A diligence in regulated markets. The firm itself is not reachable for new pitches, and inbound to the legacy email addresses or website forms is unlikely to receive a response.

What founders should know is simple: do not pitch Aspect Ventures. Use the portfolio as a reference for category fit and as a map of which other investors co-invested alongside Gouw and Fonstad in healthcare deals. If your company would have been an Aspect deal in 2017, the relevant active firms today include Acrew Capital, .406 Ventures, F-Prime, Oak HC/FT, and a long list of seed and Series A specialists. Among the founders who took Aspect capital, the firm’s reputation was for high-conviction lead investing and for senior partner attention through hard moments. That track record is worth understanding even if the firm itself is no longer writing checks.